19.92 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||19.90 x 500|
|Ask||20.15 x 100|
|Day's Range||19.61 - 20.44|
|52 Week Range||15.74 - 41.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. A lot of people feel world commerce is going to slow down, a lot of different crosscurrents because of tariffs.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ACAD totaled $633 million.
Understanding ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock was falling hard today on an article about its drug Nuplazid. Nuplazid is a drug that was given approval by the U.S. Food and Drug Administration (FDA) and started being sold to customers in June 2016. The drug was given fast-track approval by the FDA, despite concerns that it may not actually help those suffering from Parkinson’s disease.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) faded 24 percent Monday after CNN exposed the deaths of more than 700 Nuplazid patients since the drug’s June 2016 launch. The U.S. Food and Drug Administration ...
Traders flee after a troublesome news report emerged related to the company's only drug, Nuplazid. Here's what investors need to know.
Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? The drug maker’s share price continues to fall Wednesday on the heels of a disappointing 4Q earnings. Specifically, the company reported $43.6 million in 4Q17 Nuplazid sales, compared to consensus estimates of $44.3 million.
The San Diego-based company said it had a loss of 55 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
On Tuesday, ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue ...
ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.Read More...
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
The Soros Fund Management reportedly sold its entire holdings of Acadia Pharmaceuticals and Shire plc in the fourth quarter of 2017.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.